Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
1. A method of reducing triglycerides without increasing LDL-C in a subject having a fasting baseline triglyceride level of at least 500 mg/dl, the method comprising administering to the subject about 8 mg of rosiglitazone and about 4 g of a pharmaceutical composition comprising at least about 97%, by weight, ethyl eicosapentaenoate per day.
2. The method of claim 1 , wherein the pharmaceutical composition comprises substantially no docosahexaenoic acid or its esters.
3. The method of claim 1 , wherein the subject is on statin therapy.
4. The method of claim 3 , wherein the statin therapy is stable statin therapy.